Ignite Creation Date:
2024-05-06 @ 3:41 AM
Last Modification Date:
2024-10-26 @ 11:36 AM
Study NCT ID:
NCT02341911
Status:
UNKNOWN
Last Update Posted:
2022-04-20
First Post:
2015-01-13
Brief Title:
Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Carboplatin in Triple Negative Breast Cancer TNBC
Sponsor:
Fudan University
Organization:
Fudan University
Study Overview
Official Title:
A Phase II Single-center Open-Label Randomized Study of Gemcitabine Plus Cisplatin GP Versus Gemcitabine Plus Carboplatin GC as First-Line Treatment in Patients With Advanced Triple-Negative Breast Cancer
Status:
UNKNOWN
Status Verified Date:
2022-04
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TNBC
Brief Summary:
Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Carboplatin in Triple Negative Breast Cancer TNBC
Detailed Description:
A Phase II Single-center Open-Label Randomized Study of Gemcitabine Plus Cisplatin GP Versus Gemcitabine Plus Carboplatin GC as First-Line Treatment in Patients With Advanced Triple-Negative Breast Cancer
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None